LXS Stock Analysis: LANXESS Aktiengesellschaft | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 1.112m EUR | 12M Return: -39.3% | DE0005470405 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.30M
Qual. Beats: 0
Rev. Trend: -94.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LANXESS Aktiengesellschaft is a German specialty chemicals company headquartered in Cologne, with origins dating back to 1863. It operates through three reporting segments: Consumer Protection, Specialty Additives, and Advanced Intermediates, supplying chemical intermediates, additives, and consumer protection products globally.
The companys product portfolio spans material protection agents, disinfectants and preservatives, flavors and fragrances, water and liquid purification technologies, and precursors for agrochemicals and pharmaceuticals. It also produces additives, lubricants, flame retardants, plasticizers, and bromine derivatives used in rubber, plastics, paints, electronics, and construction, along with basic and fine chemicals, organometallics, and inorganic pigments for construction materials, paints, and coatings.
LANXESS sells primarily on a business-to-business basis into a broad range of end markets, including energy, natural resources, industrial applications, nutrition, health, consumer goods, agriculture, animal health, construction, chemicals, and mobility. As a specialty chemicals producer, it focuses on performance and functional chemicals formulated for specific customer applications rather than commodity-scale output, with products typically representing a small but critical component of its customers end products.
- European energy costs pressure specialty chemicals operating margins
- Automotive demand recovery lifts Specialty Additives segment revenue
- Agrochemical intermediates face Asian competition and pricing pressure
| Net Income: -669.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.62 > 1.0 |
| NWC/Revenue: 26.65% < 20% (prev 26.72%; Δ -0.07% < -1%) |
| CFO/TA 0.04 > 3% & CFO 373.0m > Net Income -669.0m |
| Net Debt (2.07b) to EBITDA (541.0m): 3.82 < 3 |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 19.37% > 18% (prev 21.19%; Δ -1.83% > 0.5%) |
| Asset Turnover: 66.09% > 50% (prev 72.96%; Δ -6.87% > 0%) |
| Interest Coverage Ratio: -3.86 > 6 (EBIT TTM -166.0m / Interest Expense TTM 43.0m) |
| A: 0.18 (Total Current Assets 3.32b - Total Current Liabilities 1.84b) / Total Assets 8.35b |
| B: -0.02 (Retained Earnings -194.0m / Total Assets 8.35b) |
| C: -0.02 (EBIT TTM -166.0m / Avg Total Assets 8.39b) |
| D: 0.71 (Book Value of Equity 3.48b / Total Liabilities 4.87b) |
| Altman-Z'' = 1.70 = BBB |
| DSRI: 1.31 (Receivables 729.0m/615.0m, Revenue 5.54b/6.15b) |
| GMI: 1.09 (GM 21.19% / 19.37%) |
| AQI: 0.88 (AQ_t 0.36 / AQ_t-1 0.41) |
| SGI: 0.90 (Revenue 5.54b / 6.15b) |
| TATA: -0.12 (NI -669.0m - CFO 373.0m) / TA 8.35b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at EUR 12.74 with a total of 555,521 shares traded. Over the past week, the price has changed by +1.92%, over one month by -16.73%, over three months by -17.54% and over the past year by -39.33%.
Current recommended Stop Loss: 12.10 (which is 5% or 1.3 ATR below the current price).
LANXESS Aktiengesellschaft has no consensus analysts rating.
P/E Forward = 14.5773
P/S = 0.2041
P/B = 0.3255
P/EG = 1.1165
Revenue TTM = 5.54b EUR
EBIT TTM = -166.0m EUR
EBITDA TTM = 541.0m EUR
Long Term Debt = 1.79b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 680.0m EUR (from shortTermDebt, last quarter)
Debt = 3.14b EUR (from shortLongTermDebtTotal, last quarter) + Leases 162.0m
Net Debt = 2.07b EUR (calculated: Debt 3.14b - CCE 1.07b)
Enterprise Value = 3.18b EUR (1.11b + Debt 3.14b - CCE 1.07b)
Interest Coverage Ratio = -3.86 (Ebit TTM -166.0m / Interest Expense TTM 43.0m)
EV/FCF = 53.88x (Enterprise Value 3.18b / FCF TTM 59.0m)
FCF Yield = 1.86% (FCF TTM 59.0m / Enterprise Value 3.18b)
FCF Margin = 1.06% (FCF TTM 59.0m / Revenue TTM 5.54b)
Net Margin = -12.06% (Net Income TTM -669.0m / Revenue TTM 5.54b)
Gross Margin = 19.37% ((Revenue TTM 5.54b - Cost of Revenue TTM 4.47b) / Revenue TTM)
Gross Margin QoQ = 21.14% (prev 19.01%)
Tobins Q-Ratio = 0.38 (Enterprise Value 3.18b / Total Assets 8.35b)
Interest Expense / Debt = 1.37% (Interest Expense 43.0m / Debt 3.14b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -124.5m (EBIT -166.0m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 3.32b / Total Current Liabilities 1.84b)
Debt / Equity = 0.90 (Debt 3.14b / totalStockholderEquity, last quarter 3.48b)
Debt / EBITDA = 3.82 (Net Debt 2.07b / EBITDA 541.0m)
Debt / FCF = 35.03 (Net Debt 2.07b / FCF TTM 59.0m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.97% (Net Income -669.0m / Total Assets 8.35b)
RoE = -18.62% (Net Income TTM -669.0m / Total Stockholder Equity 3.59b)
RoCE = -3.08% (EBIT -166.0m / Capital Employed (Equity 3.59b + L.T.Debt 1.79b))
RoIC = -1.80% (negative operating profit) (NOPAT -124.5m / Invested Capital 6.92b)
WACC = 2.99% (E(1.11b)/V(4.25b) * Re(8.55%) + D(3.14b)/V(4.25b) * Rd(1.37%) * (1-Tc(0.25)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈80.2m ; Y1≈70.3m ; Y5≈56.8m
[DCF] Fair Price = N/A (negative equity: EV 912.1m - Net Debt 2.07b = -1.15b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: -94.39 | Revenue CAGR: -8.22% | SUE: -0.48 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.66 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.27 | Chg30d=-61.89% | Revisions=+25% | GrowthEPS=-75.6% | GrowthRev=+1.6%
EPS next Year (2027-12-31): EPS=0.82 | Chg30d=+42.62% | Revisions=+0% | GrowthEPS=+199.0% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: +17% (up=2, down=1)